Identification of a Potential PPAR-Related Multigene Signature Predicting Prognosis of Patients with Hepatocellular Carcinoma.

IF 3.5 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
PPAR Research Pub Date : 2021-03-12 eCollection Date: 2021-01-01 DOI:10.1155/2021/6642939
Wenfang Xu, Zhen Chen, Gang Liu, Yuping Dai, Xuanfu Xu, Duan Ma, Lei Liu
{"title":"Identification of a Potential PPAR-Related Multigene Signature Predicting Prognosis of Patients with Hepatocellular Carcinoma.","authors":"Wenfang Xu,&nbsp;Zhen Chen,&nbsp;Gang Liu,&nbsp;Yuping Dai,&nbsp;Xuanfu Xu,&nbsp;Duan Ma,&nbsp;Lei Liu","doi":"10.1155/2021/6642939","DOIUrl":null,"url":null,"abstract":"<p><p>Peroxisome proliferator-activated receptors (PPARs) and part of their target genes have been reported to be related to the progression of hepatocellular carcinoma (HCC). The prognosis of HCC is not optimistic, and more accurate prognostic markers are needed. This study focused on discovering potential prognostic markers from the PPAR-related gene set. The mRNA data and clinical information of HCC were collected from TCGA and GEO platforms. Univariate Cox and lasso Cox regression analyses were used to screen prognostic genes of HCC. Three genes (<i>MMP1</i>, <i>HMGCS2</i>, and <i>SLC27A5</i>) involved in the PPAR signaling pathway were selected as the prognostic signature of HCC. A formula was established based on the expression values and multivariate Cox regression coefficients of selected genes, that was, risk score = 0.1488∗expression value of <i>MMP</i>1 + (-0.0393)∗expression value of <i>HMGCS</i>2 + (-0.0479)∗expression value of <i>SLC</i>27<i>A</i>5. The prognostic ability of the three-gene signature was assessed in the TCGA HCC dataset and verified in three GEO sets (GSE14520, GSE36376, and GSE76427). The results showed that the risk score based on our signature was a risk factor with a HR (hazard ratio) of 2.72 (95%CI (Confidence Interval) = 1.87 ~ 3.95, <i>p</i> < 0.001) for HCC survival. The signature could significantly (<i>p</i> < 0.0001) distinguish high-risk and low-risk patients with poor prognosis for HCC. In addition, we further explored the independence and applicability of the signature with other clinical indicators through multivariate Cox analysis (<i>p</i> < 0.001) and nomogram analysis (C-index = 0.709). The above results indicate that the combination of <i>MMP1</i>, <i>HMGCS</i>2, and <i>SLC</i>27<i>A</i>5 selected from the PPAR signaling pathway could effectively, independently, and applicatively predict the prognosis of HCC. Our research provided new insights to the prognosis of HCC.</p>","PeriodicalId":20439,"journal":{"name":"PPAR Research","volume":null,"pages":null},"PeriodicalIF":3.5000,"publicationDate":"2021-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981186/pdf/","citationCount":"7","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"PPAR Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2021/6642939","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 7

Abstract

Peroxisome proliferator-activated receptors (PPARs) and part of their target genes have been reported to be related to the progression of hepatocellular carcinoma (HCC). The prognosis of HCC is not optimistic, and more accurate prognostic markers are needed. This study focused on discovering potential prognostic markers from the PPAR-related gene set. The mRNA data and clinical information of HCC were collected from TCGA and GEO platforms. Univariate Cox and lasso Cox regression analyses were used to screen prognostic genes of HCC. Three genes (MMP1, HMGCS2, and SLC27A5) involved in the PPAR signaling pathway were selected as the prognostic signature of HCC. A formula was established based on the expression values and multivariate Cox regression coefficients of selected genes, that was, risk score = 0.1488∗expression value of MMP1 + (-0.0393)∗expression value of HMGCS2 + (-0.0479)∗expression value of SLC27A5. The prognostic ability of the three-gene signature was assessed in the TCGA HCC dataset and verified in three GEO sets (GSE14520, GSE36376, and GSE76427). The results showed that the risk score based on our signature was a risk factor with a HR (hazard ratio) of 2.72 (95%CI (Confidence Interval) = 1.87 ~ 3.95, p < 0.001) for HCC survival. The signature could significantly (p < 0.0001) distinguish high-risk and low-risk patients with poor prognosis for HCC. In addition, we further explored the independence and applicability of the signature with other clinical indicators through multivariate Cox analysis (p < 0.001) and nomogram analysis (C-index = 0.709). The above results indicate that the combination of MMP1, HMGCS2, and SLC27A5 selected from the PPAR signaling pathway could effectively, independently, and applicatively predict the prognosis of HCC. Our research provided new insights to the prognosis of HCC.

Abstract Image

Abstract Image

Abstract Image

预测肝细胞癌患者预后的潜在ppar相关多基因标记的鉴定。
据报道,过氧化物酶体增殖物激活受体(PPARs)及其部分靶基因与肝细胞癌(HCC)的进展有关。HCC预后不容乐观,需要更准确的预后指标。这项研究的重点是发现ppar相关基因集的潜在预后标志物。通过TCGA和GEO平台收集HCC mRNA数据和临床信息。采用单因素Cox和lasso Cox回归分析筛选HCC预后基因。选择三个参与PPAR信号通路的基因(MMP1、HMGCS2和SLC27A5)作为HCC的预后标志。根据所选基因的表达值和多变量Cox回归系数建立公式:风险评分= 0.1488∗MMP1表达值+(-0.0393)∗HMGCS2表达值+(-0.0479)∗SLC27A5表达值。在TCGA HCC数据集中评估了三基因标记的预后能力,并在三个GEO集(GSE14520, GSE36376和GSE76427)中进行了验证。结果显示,基于我们签名的风险评分是HCC生存的一个危险因素,HR(危险比)为2.72 (95%CI(置信区间)= 1.87 ~ 3.95,p < 0.001)。该特征可以显著(p < 0.0001)区分HCC预后不良的高危和低危患者。此外,我们通过多变量Cox分析(p < 0.001)和nomogram分析(C-index = 0.709)进一步探讨了该特征与其他临床指标的独立性和适用性。以上结果表明,PPAR信号通路中选择的MMP1、HMGCS2、SLC27A5联合可有效、独立、应用地预测HCC预后。我们的研究为HCC的预后提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
PPAR Research
PPAR Research MEDICINE, RESEARCH & EXPERIMENTAL-
CiteScore
6.20
自引率
3.40%
发文量
17
审稿时长
12 months
期刊介绍: PPAR Research is a peer-reviewed, Open Access journal that publishes original research and review articles on advances in basic research focusing on mechanisms involved in the activation of peroxisome proliferator-activated receptors (PPARs), as well as their role in the regulation of cellular differentiation, development, energy homeostasis and metabolic function. The journal also welcomes preclinical and clinical trials of drugs that can modulate PPAR activity, with a view to treating chronic diseases and disorders such as dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, and obesity.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信